November 27, 2017

Regeneron Study of Nesvacumab Discontinued

by

Regeneron Study of Nesvacumab Discontinued

It was recently reported here that nesvacumab (REGN910) was being tested in combination with Eylea (Regeneron) as a potential treatment for wet AMD. Regeneron, however, reported on November 27 that the results “did not provide sufficient differentiation to warrant Phase 3 development.” The Phase 2 trials have, therefore, been discontinued, and research data will be released at a future date.

We offer resources and free materials for those living with low vision.

View Resources